Current Report Filing (8-k)
November 08 2016 - 4:48PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 8,
2016 (November 7, 2016)
Neuralstem, Inc.
(Exact name of registrant as specified in Charter)
Delaware
|
|
000-1357459
|
|
52-2007292
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
20271 Goldenrod Lane, 2
nd
Floor, Germantown, Maryland
20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On November 7, 2016, representatives of Neuralstem, Inc. (the “Company”)
presented a poster entitled “Comprehensive In Vivo Nonclinical Safety Assessment of NSI-189, a Small Molecule New Chemical Entity
for the Treatment of Major Depressive Disorder,” at the 2016 American College of Toxicology Annual Meeting in Baltimore,
Maryland. A copy of the poster is attached to this report as Exhibit 99.01.
The information contained in this Item 7.01 to this Current Report
on Form 8-K and the exhibit attached hereto pertaining to this item shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
a filing. The information set forth in the exhibits to this Form 8-K relating to this item 7.01 shall not be deemed an admission
as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of
Regulation FD.
Item 9.01 Financial Statement and
Exhibits.
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.01
|
|
Poster Presented on November 7, 2016
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 8, 2016
|
Neuralstem, Inc.
|
|
|
|
|
|
/s/ Richard Daly
|
|
By: Richard Daly
|
|
Chief Executive Officer
|
INDEX OF EXHIBITS
|
Exhibit
No.
|
|
Description
|
|
|
99.01
|
|
Poster Presented on November 7, 2016
|
|
|
|
|
|
|
|
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024